Majda Hadziahmetovic is an Ophthalmology physician affiliated with Duke University. OpenAlex indexes 72 publications with 2,085 citations (h-index 19).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2351 Erwin Rd
Durham, NC 277054699
Telephone
919-684-9010Registry record last updated 15 Aug 2016.
Industry payments
13 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Ocular Therapeutix, Inc.Program year20251 payment$10,000openpaymentsdata.cms.gov ↗
- ABBVIE INC.Program year20252 payments
- Genentech USA, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
93.8%Antineovascularisation agents92.3%Faricimab-svoa100%Part B, office-administered≥66 patientsCorticosteroid1.3%Dexamethasone85%Prednisolone Acetate15%Part D + Part B≥22 patients+ 3 more classes in this area
Cancer & immunology
6%Vascular Endothelial Growth Factor Inhibitor5.9%Aflibercept97%Bevacizumab3%Part B, office-administered≥153 patientsCalcineurin inhibitor0.1%Restasis100%Part D≥12 patientsMusculoskeletal
0.1%Cyclooxygenase Inhibitor0.1%Ketorolac Tromethamine100%Part D≥12 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2023–2023 per NIH RePORTER. The latest:
- Learning-based 3D modeling of AMD to assess disease progression and response to treatment
Duke University
FY2023$433,841R21EY033480
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Artificial intelligence in age-related macular degeneration: Advancing diagnosis, prognosis, and treatment
Survey of Ophthalmology
2025 - Evaluating photodynamic therapy as an adjuvant treatment for neovascular AMD: A comprehensive meta-analysis
Asia-Pacific Journal of Ophthalmology
2025 - Effect of Faricimab on Visual Acuity and Retinal Structure in Neovascular Age-Related Macular Degeneration Previously Treated With Anti-VEGF Therapy
Journal of VitreoRetinal Diseases
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Robert Califf, MD
Duke University
Pamela Douglas, MD
Duke University
Adrian Hernandez, MD
Duke University
John Perfect, MD
Duke University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”